EUVIMEDEUVIMED entdecken
Crossref

Discovery of Selective Inhibitors for β-Actin Polymerization as Potential Anticancer Agents In Vitro and In Vivo

Weixiong Chen, Shilong Hao, Donghui Sun, Jiarui Chang, Meng Li, Zongjing Hu, Jinhua Liu, Yikai Xu, Ya Gao, Tong Zhu iD, Shunying Liu iD

Journal of Medicinal Chemistry · 11.06.2026 · 69 (11) · 13345-13366

DOI: 10.1021/acs.jmedchem.6c00299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.05.2026. Verfasst von Weixiong Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Actins. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing, National Basic Research Program of China (973 Program), National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

No selective actin inhibitor has been developed due to the high homology of actin isoforms. Given the distributions of cysteine residues among actin isoforms, we propose the covalent small-molecule targeting approach offers a distinct path to achieve isoform selectivity. Combining phenotypic screening of our in-house covalent compound library and structural optimizations, we identified a novel and selective β-actin inhibitor C25. ABPP protein affinity enrichment and mechanistic investigations discovered C25 specifically targeted to β-actin but not α- or γ-actin and inhibited its polymerization to disrupt the actin cytoskeleton and lead to cell death in143B cells. C25 exhibits potent anticancer activity both in vitro (IC50 = 0.015 μM) and in vivo (TGI = 66%) and shows no obvious toxicity at the tested dosage. To our knowledge, C25 represents the first selective inhibitor of β-actin. This provides valuable insights and a foundation for subsequent research on the selectivity of actins and related drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsActinsHumansAnimalsStructure-Activity RelationshipCell Line, TumorDrug DiscoveryPolymerizationMiceDrug Screening Assays, Antitumor

Substanzen

Antineoplastic AgentsActins

Autor:innen und Institutionen

  • Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
  • School of Mathematics, Physics and Statistics, Shanghai University of Engineering Science, Shanghai 201620, China.
  • Chongqing Institute of East China Normal University, Chongqing 401120, China.

ORCID-Profile: Tong Zhu, Shunying Liu

Förderung

  • Natural Science Foundation of Chongqing
  • National Basic Research Program of China (973 Program)
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Chen, W., Hao, S., Sun, D., Chang, J., Li, M., Hu, Z., Liu, J., Xu, Y., Gao, Y., Zhu, T., & Liu, S. (2026). Discovery of Selective Inhibitors for β-Actin Polymerization as Potential Anticancer Agents In Vitro and In Vivo. Journal of Medicinal Chemistry, 69(11), 13345-13366. https://doi.org/10.1021/acs.jmedchem.6c00299

Vancouver

Chen W, Hao S, Sun D, Chang J, Li M, Hu Z, et al. Discovery of Selective Inhibitors for β-Actin Polymerization as Potential Anticancer Agents In Vitro and In Vivo. Journal of Medicinal Chemistry. 2026;69(11):13345-13366. doi:10.1021/acs.jmedchem.6c00299

BibTeX
@article{Chen2026,
  author = {Chen, Weixiong and Hao, Shilong and Sun, Donghui and Chang, Jiarui and Li, Meng and Hu, Zongjing and Liu, Jinhua and Xu, Yikai and Gao, Ya and Zhu, Tong and Liu, Shunying},
  title = {Discovery of Selective Inhibitors for β-Actin Polymerization as Potential Anticancer Agents In Vitro and In Vivo},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {11},
  pages = {13345--13366},
  doi = {10.1021/acs.jmedchem.6c00299}
}
Kostenlos starten →